The vagus nerve’s role in autoimmune disease is one of the most significant stories in modern immunology. In 2000, neurosurgeon Kevin Tracey discovered that electrically stimulating the vagus nerve in animals could suppress the production of TNF-alpha and other inflammatory cytokines — a finding that launched an entirely new field called bioelectronic medicine. Twenty-five years later, that discovery has produced an FDA-approved treatment for rheumatoid arthritis and a fundamentally new understanding of how the nervous and immune systems communicate.
The Cholinergic Anti-Inflammatory Pathway
The mechanism connecting the vagus nerve to immune regulation is called the cholinergic anti-inflammatory pathway (CAP). It works through a specific circuit:
Vagal afferent fibres detect inflammatory signals in the periphery — cytokines, pathogen-associated molecules, damage signals — and relay that information to the brainstem. The brain processes this input and activates vagal efferent fibres that travel to the celiac ganglion in the abdomen. From there, the signal transfers to the splenic nerve, which innervates the spleen — the body’s largest reservoir of immune cells.
In the spleen, norepinephrine released by the splenic nerve activates a specific subset of T lymphocytes (choline acetyltransferase-positive T cells) that produce acetylcholine. This acetylcholine then binds to alpha-7 nicotinic acetylcholine receptors (a7nAChR) on macrophages, suppressing their production of TNF-alpha, IL-1beta, IL-6, and other pro-inflammatory cytokines. Critically, this pathway suppresses excessive inflammation without blocking the immune response entirely — it modulates rather than immunosuppresses.
This vagal-splenic circuit is sometimes called the “inflammatory reflex” because it functions as a reflex arc: inflammation is sensed, the signal is processed centrally, and an anti-inflammatory response is generated, all through neural pathways that operate far faster than humoral (blood-borne) immune regulation.
Why This Matters for Autoimmune Disease
Autoimmune diseases — rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, type 1 diabetes, and roughly 80 other conditions — share a common feature: the immune system generates excessive, misdirected inflammation against the body’s own tissues. Current treatments mostly work by broadly suppressing immune function, which reduces autoimmune damage but also increases susceptibility to infections and cancer.
The vagal anti-inflammatory pathway offers a different approach: rather than flooding the body with immunosuppressive drugs, electrical stimulation of the vagus nerve activates the body’s own built-in inflammation-control circuit. Several lines of evidence suggest this pathway is already disrupted in autoimmune conditions.
Patients with rheumatoid arthritis tend to have reduced heart rate variability (HRV) — a standard measure of vagal tone — compared to healthy controls. Reduced vagal tone correlates with higher levels of circulating inflammatory cytokines. In animal models of arthritis, cutting the vagus nerve worsens joint inflammation, while stimulating it reduces swelling and joint damage. This pattern suggests that insufficient vagal anti-inflammatory signalling may contribute to — or at least fail to restrain — autoimmune inflammation.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
- Breathwork
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
SetPoint Medical and the FDA Approval
The most dramatic clinical translation came from SetPoint Medical, a company founded on Tracey’s research. Their implantable bioelectronic device stimulates the vagus nerve with precisely calibrated electrical pulses designed to activate the cholinergic anti-inflammatory pathway.
In July 2025, the SetPoint Medical device received FDA approval for treatment-resistant rheumatoid arthritis — making it the first bioelectronic medicine approved for an autoimmune condition. The approval was based on clinical trials showing that RA patients who had failed multiple biologic therapies achieved meaningful improvements in disease activity scores (DAS28) with vagus nerve stimulation. Some patients achieved clinical remission, and the anti-inflammatory effects persisted with chronic stimulation.
What makes this approval significant beyond rheumatoid arthritis is its proof of concept. If electrically activating the vagal anti-inflammatory circuit can suppress joint inflammation in RA, the same mechanism should theoretically apply to other autoimmune conditions driven by TNF-alpha and IL-6. Clinical trials are underway or planned for Crohn’s disease, ulcerative colitis, and other inflammatory conditions.
Specific Autoimmune Conditions and the Vagus Nerve
Rheumatoid arthritis: The best-studied autoimmune application for VNS. Beyond the SetPoint device, studies have shown that auricular (ear-based) transcutaneous VNS (taVNS) can reduce inflammatory markers in RA patients, though the evidence is less robust than for implanted devices that directly stimulate the cervical vagus trunk.
Inflammatory bowel disease (IBD): The vagus nerve heavily innervates the gut and regulates intestinal inflammation through both the cholinergic anti-inflammatory pathway and direct effects on gut immune cells. Pilot studies of implanted VNS in Crohn’s disease have shown improvement in clinical symptoms and endoscopic inflammation scores in some patients. The vagus also modulates the gut microbiome, which is increasingly recognised as a driver of IBD. Reduced vagal tone has been documented in both Crohn’s disease and ulcerative colitis.
Multiple sclerosis (MS): Preclinical evidence suggests vagal stimulation can reduce neuroinflammation and promote remyelination in animal models of MS. The mechanisms may involve both direct anti-inflammatory effects and modulation of blood-brain barrier permeability. Human clinical data is limited but an area of active investigation.
Lupus (SLE): Systemic lupus erythematosus involves multiple inflammatory pathways, many of which are influenced by vagal anti-inflammatory signalling. Reduced HRV has been documented in lupus patients and correlates with disease activity. VNS trials in lupus are in early stages.
Type 1 diabetes: While primarily a T-cell-mediated autoimmune destruction of pancreatic beta cells, the vagus nerve’s role in pancreatic innervation and its broader anti-inflammatory effects make it a theoretical target. Animal studies have shown protective effects of vagal stimulation on beta cell preservation, but human evidence is preliminary.
Non-Invasive Approaches and Their Limitations
Given the cost and invasiveness of implanted VNS devices, there’s significant interest in whether non-invasive methods can meaningfully engage the cholinergic anti-inflammatory pathway.
Transcutaneous auricular VNS (taVNS) stimulates Arnold’s nerve in the ear canal. Several small studies have shown reductions in inflammatory markers (CRP, TNF-alpha, IL-6) with regular taVNS use. However, the effect size appears smaller than with implanted cervical VNS, likely because auricular stimulation activates vagal afferents (sensory fibres projecting to the brainstem) rather than directly stimulating the efferent (motor) fibres that drive the splenic anti-inflammatory circuit. The brain must relay the signal, and some attenuation occurs.
HRV biofeedback and slow breathing can increase vagal tone as measured by HRV, and some studies suggest they reduce inflammatory markers. However, the magnitude of anti-inflammatory effect achievable through breathing techniques alone is likely insufficient to meaningfully control active autoimmune disease. These approaches are better understood as complementary strategies — potentially helpful alongside medical treatment, not as replacements for it.
Exercise is one of the most reliable ways to improve vagal tone and reduce systemic inflammation, with benefits documented across multiple autoimmune conditions. Regular moderate exercise reduces CRP, IL-6, and TNF-alpha while improving HRV — essentially enhancing the same pathway that VNS targets, though through different mechanisms including changes in muscle-derived anti-inflammatory myokines.
The Broader Implications
The vagus nerve’s role in autoimmune disease represents a conceptual shift in how we think about immune regulation. Rather than the immune system operating as an autonomous entity, it’s increasingly clear that the nervous system actively monitors and regulates immune activity in real time. The vagus nerve is the primary neural conduit for this regulation.
This doesn’t mean the vagus nerve is the cause of autoimmune diseases — these conditions have complex genetic, environmental, and immunological origins. But it does mean that vagal dysfunction may contribute to the failure to restrain autoimmune inflammation, and that restoring vagal anti-inflammatory signalling — whether through implanted devices, transcutaneous stimulation, or lifestyle interventions — represents a genuinely new therapeutic avenue that works alongside existing treatments rather than replacing them.
The vagus nerve’s role as the body’s built-in anti-inflammatory circuit is just one of its remarkable functions. For a comprehensive, evidence-based guide to this nerve and how to support it, get the Vagus Nerve & Me eBook.
